Literature DB >> 22547624

HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients.

Alejandro Gonzalez-Serna1, María Concepción Romero-Sánchez, Sara Ferrando-Martinez, Miguel Genebat, Francesc Vidal, Maria Ángeles Muñoz-Fernández, María Antonia Abad, Manuel Leal, Ezequiel Ruiz-Mateos.   

Abstract

We analyzed the evolution of viral tropism after 8 days of maraviroc monotherapy, i.e., we used the maraviroc clinical test (MCT), in 21 patients with and 14 without virological response to the drug (MCT(+) and MCT(-) patients, respectively). No increases in CXCR4 inferred viral loads (X4IVLs) were observed in MCT(+) patients, while X4IVLs increased only in MCT(-) patients, with X4IVLs of >2 log(10) HIV RNA copies/ml. These results shed light on the evolution of viral tropism under a CCR5 antagonist in vivo.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22547624      PMCID： PMC3393450          DOI： 10.1128/AAC.00507-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors.

Authors:  Jonathan Toma; Jeannette M Whitcomb; Christos J Petropoulos; Wei Huang
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

2.  Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.

Authors:  Miguel Genebat; Ezequiel Ruiz-Mateos; Ildefonso Pulido; Alejandro González-Serna; Antonio García-Pergañeda; Gema Méndez; María Concepción Romero-Sánchez; Sara Ferrando-Martínez; Manuel Leal
Journal:  Curr HIV Res       Date:  2010-09       Impact factor: 1.581

3.  Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

Authors:  Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches.

Authors:  Alejandro Gonzalez-Serna; Manuel Leal; Miguel Genebat; Maria Antonia Abad; Antonio Garcia-Perganeda; Sara Ferrando-Martinez; Ezequiel Ruiz-Mateos
Journal:  J Clin Microbiol       Date:  2010-10-13       Impact factor: 5.948

5.  Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Authors:  M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

6.  Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients.

Authors:  Miguel Genebat; Ezequiel Ruiz-Mateos; Juan A León; Alejandro González-Serna; Ildefonso Pulido; Inmaculada Rivas; Sara Ferrando-Martínez; Berta Sánchez; Ma Angeles Muñoz-Fernández; Manuel Leal
Journal:  J Antimicrob Chemother       Date:  2009-08-11       Impact factor: 5.790

Review 7.  Tropism testing in the clinical management of HIV-1 infection.

Authors:  Nina H Lin; Daniel R Kuritzkes
Journal:  Curr Opin HIV AIDS       Date:  2009-11       Impact factor: 4.283

8.  Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism.

Authors:  Stéphanie Raymond; Pierre Delobel; Maud Mavigner; Michelle Cazabat; Corinne Souyris; Karine Sandres-Sauné; Lise Cuzin; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177
  8 in total
  3 in total

1.  Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.

Authors:  A Gonzalez-Serna; M Genebat; M De Luna-Romero; L Tarancon-Diez; B Dominguez-Molina; Y M Pacheco; M A Muñoz-Fernández; M Leal; E Ruiz-Mateos
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.

Authors:  Richard M Gibson; Ashley M Meyer; Dane Winner; John Archer; Felix Feyertag; Ezequiel Ruiz-Mateos; Manuel Leal; David L Robertson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

3.  Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.

Authors:  Alejandro Gonzalez-Serna; Miguel Genebat; Ezequiel Ruiz-Mateos; Manuel Leal
Journal:  Drug Des Devel Ther       Date:  2016-01-18       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.